Literature DB >> 14982797

In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Charles E Edmiston1, Candace J Krepel, Gary R Seabrook, Lewis R Somberg, Atilla Nakeeb, Robert A Cambria, Jonathan B Towne.   

Abstract

The in vitro activities of moxifloxacin, ciprofloxacin, levofloxacin, gatifloxacin, imipenem, piperacillin-tazobactam, clindamycin, and metronidazole against 900 surgical isolates were determined using NCCLS testing methods. Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14982797      PMCID： PMC353113          DOI： 10.1128/AAC.48.3.1012-1016.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.

Authors:  G Ackermann; R Schaumann; B Pless; M C Claros; E J Goldstein; A C Rodloff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-03       Impact factor: 3.267

Review 2.  Diabetic foot ulcers and infections: current concepts.

Authors:  Jason H Calhoun; Kristi A Overgaard; C Melinda Stevens; James P F Dowling; Jon T Mader
Journal:  Adv Skin Wound Care       Date:  2002 Jan-Feb       Impact factor: 2.347

3.  Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.

Authors:  Dhananjai J Menzies; Pierre A Dorsainvil; Burke A Cunha; Diane H Johnson
Journal:  Am J Med       Date:  2002-08-15       Impact factor: 4.965

Review 4.  Antimicrobial safety and tolerability: differences and dilemmas.

Authors:  L A Mandell; P Ball; G Tillotson
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

5.  Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.

Authors:  M H Nguyen; V L Yu; A J Morris; L McDermott; M W Wagener; L Harrell; D R Snydman
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

6.  Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.

Authors:  Josette Behra-Miellet; Luc Dubreuil; Estelle Jumas-Bilak
Journal:  Int J Antimicrob Agents       Date:  2002-11       Impact factor: 5.283

Review 7.  Quinolone activity against anaerobes.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1999       Impact factor: 9.546

8.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.

Authors:  Ellie J C Goldstein
Journal:  Clin Infect Dis       Date:  2002-09-01       Impact factor: 9.079

10.  Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.

Authors:  Kenneth E Aldridge; Deborah Ashcraft; Megan O'Brien; Charles V Sanders
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more
  24 in total

1.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.

Authors:  Jolanta Majcher-Peszynska; Marko Sass; Sora Schipper; Viktor Czaika; Andreas Gussmann; Ralf Lobmann; Ralf G Mundkowski; Christoph Luebbert; Peter Kujath; Bernhard R Ruf; Horst Koch; Wolfgang Schareck; Ernst Klar; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2010-09-25       Impact factor: 2.953

Review 3.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

Authors:  Jan J De Waele; Jose M Tellado; Günter Weiss; Jeffrey Alder; Frank Kruesmann; Pierre Arvis; Tajamul Hussain; Joseph S Solomkin
Journal:  Surg Infect (Larchmt)       Date:  2014-05-15       Impact factor: 2.150

5.  Efficacy of Triple Antibiotic Paste, Moxifloxacin, Calcium Hydroxide And 2% Chlorhexidine Gel In Elimination of E. Faecalis: An In vitro Study.

Authors:  Ashik Ali Lakhani; K S Sekhar; Pankaj Gupta; Bellam Tejolatha; Anjali Gupta; Shruti Kashyap; Veena Desai; Shanin Farista
Journal:  J Clin Diagn Res       Date:  2017-01-01

6.  Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Authors:  B J Gardiner; A Y Tai; D Kotsanas; M J Francis; S A Roberts; S A Ballard; R K Junckerstorff; T M Korman
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

7.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

8.  In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.

Authors:  C-Y Liu; C-L Lu; Y-T Huang; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-08       Impact factor: 3.267

Review 9.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.

Authors:  Andreas D Rink; Heino Stass; Heinz Delesen; Dagmar Kubitza; Karl-Heinz Vestweber
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.